CHRONIC DIARRHEA: DIAGNOSTIC AND THERAPEUTIC TACTICS


Cite item

Full Text

Abstract

The article discusses the problem of the origin, diagnosis and treatment of chronic diarrhea in children. Chronic diarrhea is heterogeneous group with respect to pathogenesis, and is characterized by common feature: a violation of the physico-chemical properties of the feces. Typical clinical manifestations of chronic diarrhea are presented; features of diagnosis and treatment are examined. The potentials for use of probiotics, in particular drug Enterol, are considered.

References

  1. Schiller LR, Sellin JH. Diarrhea. In: Feldman M, Friedman LS, Sleisenger MH, et al. Sleisenger & Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 7th ed. Philadelphia, Saunders 2002:131-53.
  2. Camilleri M. Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. Clin Gastroenterol Hepatol 2004;2:198-206.
  3. Schiller LR. Chronic diarrhea. Gastroenterology 2004;127:287-93.
  4. Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. Gut 2004;53:1-4.
  5. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
  6. Headstrom PD, Surawicz CM. Chronic diarrhea. Clin Gastroenterol Hepatol 2005;3:734-37.
  7. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003;17:905-12.
  8. Савоненкова Л.Н., Арямкина О.Л. Вопросы клиники, патоморфогенеза и исходы гастроинтестинального туберкулеза // Гастроэнтерология Санкт-Петербурга 2004. № 1. С. 23-24.
  9. Бондаренко В.М. Роль условно-патогенных бактерий кишечника в полиорганной патологии человека. М., 2007. 64 с.
  10. Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008;135:568-79.
  11. Vakiani E, Arguelles-Grande C,Mansukhani MM, et al. Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Mod Pathol 2010;23:12-26.
  12. Green PH, Yang J, Cheng J, et al. An association between microscopic colitis and celiac disease. Clin Gastroenterol Hepatol 2009;7:1210-6.
  13. Pardi DS. Microscopic colitis: an update. Inflamm Bowel Dis 2004;10:860-70.
  14. Korkut M, Erhan Y, Osmanoglu H, et al. A case of severe ischemic colitis caused by systemic lupus erythematosus. J Pak Med Assoc 1995;45:271-2.
  15. Okada M, Konishi F, Sakuma K, et al. Perforation of the sigmoid colon with ischemic change due to polyarteritis nodosa. J Gastroenterol 1999;34:400-4.
  16. Lie T. Isolated necrotizing and granulomatous vasculitis causing ischemic bowel disease in primary Sjogren'e syndrome. J Rheumatol 1995;22:2375-7.
  17. Walker AM, Bohn RL, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004;99:1333-7.
  18. Chang L, Kahler KH, Sarawate C, et al. Assessment of potential risk factors associated with ischemic colitis. Neurogastroenterol Motil 2008;20:36-42.
  19. Hass DJ, Kozush P, Brandt LJ. Pharmacologically mediated colon ischemia. Am J Gastroenterol 2007;102:1765-80.
  20. Tada H, Saitoh S, Nakagawa y, et al. Ischemic colitis during interferon alpha treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582-4.
  21. Carratu R, Parisi P, Agozzino A. Segmental ischemic colitis associated with nonsteroidal anti-inflammatory drugs. J Clin Gastroenterol 1993;16:31-4.
  22. Dirkx CA, Gerscovich EO. Sonographic findings in methamphetamine induced ischemic colitis. J Clin Ultrasound 1998;26:479-82.
  23. Алекберова З.С. Болезнь Бехчета у детей // Вопросы современной педиатрии 2009. Т. 8. № 6. С. 64-70.
  24. International ESPGHAN School. Scientific publication book. Moscow 2010.
  25. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is s sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
  26. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
  27. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
  28. Одинцева В.Е., Александрова В.А. Современные особенности клинических проявлений, методов диагностики и лечения гельминтно-протозойных инвазий у детей // Вестник Санкт-Петербургской медицинской академии последипломного образования 2010. Т. 2. № 1. С. 42-49.
  29. Rahiar JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCC 2009;3(2):47-140.
  30. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
  31. Парфенов А.И., Крумс Л.М. Холагенная диарея: особенности патогенеза, клиники и лечения // РМЖ 2009. № 2. С. 114-18.
  32. Chang EJ. Rotavirus infection in children. Pediatric Infect Dis J 2002;21(2):97-102.
  33. Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54:1-16.
  34. Camillery M. Chronic diarrhea. Clin Gastroenterol Hepatol 2004;2(3):198-206.
  35. Shulman RJ, Wong WW, Smith EO. Influence of changes in lactase activity and small-intestinal mucosal growth on lactose digestion and absorption in preterm infants. Am J Clin Nutrition 2005;81(2):472-9.
  36. Sandeep KG, Sonny KFC. Disaccharidase activities in children: normal values and comparison based on symptoms and hystologic changes. Nutr Infant 2004;4:7-13.
  37. McClure RJ, Newell SJ. Randomized controlled study of digestive enzyme activity following trophic feeding. Acta Paediatr 2002;91(3):6-292.
  38. de Vrese M, Siebe R, Stransky M. Lactose in human dietetics. Nutrition infantile 2004;4:4-7.
  39. Ojetti V, Nucera G, Migneco A, et al. High prevalence of celiac disease in patients with lactose intolerance. Digestion 2005;71:106-10.
  40. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in celiac disease. Lancet. 2003;362:30-37.
  41. Hernanz A, Polanco I, Codoceo R, et al. Gastrointestinal peptide profile in children with celiac disease. J Pediatr Gastroenterol Nutr 1987;6:341-5.
  42. Linnestad P, Erichsen A, Fausa O, et al. The release of human pancreatic polypeptide, gastrin, gastric inhibitory polypeptide, and somatostatin in celiac disease related to the histological appearance of jejunal mucosa before and 1 year after gluten withdrawal. Scand J Gastroenterol 1983;18:169-75.
  43. Petersen JM, Forsmark CE. Chronic pancreatitis and maldigestion. Semin Gastrointest Dis 2002;13:191-99.
  44. O'Peilly CM, Winpenny JP, Argent BE, et al. Cystic fibrosis transmembrane conductance regulator currents in Guinea pig pancreatic duct cells: inhibition by bicarbonate ions. Gastroenterol 2000;118(6):1187-96.
  45. Jarrett RJ. Impaired glucose tolerance and diabetes: WHO criteria. Br Med J (Clin Res Ed) 1981;282-990.
  46. Tandon RK, Sato N, Garg PK, et al. Crronic pancreatitis: Asia-Pacific consensus report. Gastroenterol Hepatol 2002;17:508-18.
  47. Gredal C. The Lundh test and faecal elastase-1 determination in chronic pancreatitis: a comparative study. Pancreatolody 2003;3(5):389-94.
  48. Glasbrenner B, Kahl S, Malfertheiner P. Modern Diagnostics of Cronic Pancreatitis. Eur J Gastroenterol Hepatol 2002;14(9):935-41.
  49. Tamboli CP, Neut C, Desreumaux P, et al. Disbiosis in inflammatory bowel disease. Gut 2004;53:1-4.
  50. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
  51. Swidsinki A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of mucosal flora in patients with inflammatory bowel disease. JCM 2005;43:3380-9.
  52. Gedek S. Adherence of Escherichia coli O157 and the Salmonella typhimurum mutant DT101 to a surface of Saccharomyces boulardii. Mycoses 1999;42:261-64.
  53. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes infect 2002;4:733-9.
  54. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16(8):1461-7.
  55. McFarland LV, Surawicz CM, Elmer GE. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994;271:1913-8.
  56. Rambaud JC, Buts JP, Corthier G, Flourie B. Gut microflora. Digestive physiology and pathology. John Libbey Eurotext, Paris 2006.
  57. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008;27:104-19.
  58. Girard P, Pansart Y, Gillardin JM. Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Nitric Oxide 2005;13:163-69.
  59. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006;343(1):69-76.
  60. Nguyen-Phuoc BK, Vatier J. Etude in vitro du pouvoir chelateur de la smectite vis-a-vis des sels buliaires et des lysolecithines. Gastroenterol Clin Biol 1984;8:877-78.
  61. Rateau JG, Morgant G, Droy-Priot MT. A historical, enzymatic and water-electrolyte study of the action of smectite, a mucoprotective clay, on experimental infectious diarrhoea in the rabbit. Current Medical Research and Opinion 1982;8(4):224-32.
  62. Benhamou PH, Berlier P, Langue J, Dupont C. Intestinal manifestations during antibiotic treatments in children: a prospective stady. Gastroenterology 1995;108(4):A273.
  63. Droy Lefaix MT. Smectite et barriere muqueuse intestinale. Revue Med Vet 1987;138:411-21.
  64. Arbeille PH, Schillio Y, Bodard S. Va lue of using a gaz reductor (Diosmectite) for the preparation of patients prior to the echography of the epigastric area Gastroenterology 1991;100 (5Part2):A347.
  65. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayedrelease capsules (Creon) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gasteroenterol 2010;105:2276-86.
  66. Safdi M, Bekal PK, Martin S, et al. The effects of oral pancreatic enzymes (creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 2006;33:156-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies